Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's in stroke compound supply deal with Sygnis

Dr Reddy's signs an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient for stroke and other neurodegenrative disorders

Indian pharmaceutical company Dr Reddy's Laboratories has signed an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient used in the treatment of stroke and other neurodegenrative disorders.

The active ingredient is biological molecule AX200, which is being developed by Sygnis. The company successfully completed phase IIa clinical trials of the compound in September 2007, which demonstrated safety and efficacy in patients with acute stroke.

Sygnis plans to begin phase IIb trial in H2 2008. The study will be an efficacy trial in acute stroke. AX200 is the most advanced product in Sygnis' portfolio.

Cartikeya Reddy, head of biologics, at Dr Reddy's, said: "Our strategic decision to exclusively produce a biological molecule for a partner is a first in the history of Dr Reddy's and fits very well within our custom pharmaceutical services' business model. We are very optimistic that AX200 will continue to show real potential in the treatment of acute stroke with the potential to be used in the treatment of other degenerative neurological diseases."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics